Intellia Therapeutics to Present at ASH
Intellia Therapeutics (NTLA) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, GA, as well as virtually, December 11-14, 2021.
From the CSO at Intellia Therapeutics
Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics, said, “As we continue to advance our full-spectrum strategy, we look forward to sharing preclinical data from our ex vivo platform with the research community at this year’s ASH Annual Meeting. The data will feature our novel allogeneic technology designed to overcome rejection by host T and NK cells without the need for host immune suppression, as well as highlight our clinical-scale manufacturing process developed for NTLA-5001, our TCR-based T cell therapeutic candidate for the treatment of acute myeloid leukemia. Together, the data support our progress toward developing engineered cell therapies with the potential to transform the lives of people living with life-threatening diseases.”
********************
ASH Annual Meeting Poster Presentations
- Title: A Novel Strategy for Off-the-shelf T Cell Therapies Evading Host T Cell and NK Cell Rejection
- Abstract number: 1711
- Date & Time: Saturday, December 11, 2021, 5:30 p.m. – 7:30 p.m. ET
- Location: Georgia World Congress Center, Hall
- Presenting Author: Yong Zhang, Ph.D., associate director, Cell Therapy
- Title: Clinical-scale Production and Characterization of NTLA-5001 – a Novel Approach to Manufacturing CRISPR/Cas9 Engineered T-cell Therapies
- Abstract number: 3881
- Date & Time: Monday, December 13, 2021, 6:00 p.m. – 8:00 p.m. ET
- Location: Georgia World Congress Center, Hall B5
- Presenting Author: Daniel Cosette, senior scientist, Process Development
Additional data collected will be included in final meeting presentations. All abstracts for the ASH Annual Meeting will be available on the ASH website.
About Intellia Therapeutics
Intellia Therapeutics develops novel, potentially curative therapeutics using CRISPR/Cas9 technology. To fully realize the transformative potential of CRISPR/Cas9, Intellia is pursuing two primary approaches:
The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues.
The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
Intellia’s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, enabled the company to take a leadership role in harnessing the full potential of CRISPR/Cas9 in order to create new classes of genetic medicine.
Prohost Observations
Intellia means to share with investors the preclinical data from its ex vivo platform at the ASH Annual Meeting.It is important to know about the data are important as they will feature the novel allogeneic technology designed to overcome rejection by host T and NK cells without the need for host immune suppression, as well as highlight its clinical-scale manufacturing process developed for the company product candidate, NTLA-5001, for the treatment of acute myeloid leukemia.
We will surely not to miss the firm’s presentation at the ASH meeting.
Click here to read more about Intellia Therapeutics.
News & Comments
November 6, 2021
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH
Intellia Therapeutics to Present at ASH
Intellia Therapeutics (NTLA) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, GA, as well as virtually, December 11-14, 2021.
From the CSO at Intellia Therapeutics
Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer, Intellia Therapeutics, said, “As we continue to advance our full-spectrum strategy, we look forward to sharing preclinical data from our ex vivo platform with the research community at this year’s ASH Annual Meeting. The data will feature our novel allogeneic technology designed to overcome rejection by host T and NK cells without the need for host immune suppression, as well as highlight our clinical-scale manufacturing process developed for NTLA-5001, our TCR-based T cell therapeutic candidate for the treatment of acute myeloid leukemia. Together, the data support our progress toward developing engineered cell therapies with the potential to transform the lives of people living with life-threatening diseases.”
Other Articles